Diurnal Group PLC - Cardiff, Wales-based pharmaceutical company - Granted European patent for Chronocort to treat patients with congenital adrenal hyperplasia and adrenal insufficiency. The patent provides in-market European protection until 2033 in all designated states of the European Patent Convention. "The equivalent patents from the same family are already granted in the UK, Canada, Mexico, New Zealand, Japan, Australia, Israel, South Africa, South Korea and in the US," Diurnal adds.
Current stock price: 62.00 pence
Year-to-date change: up 8.8%
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.